LifeMD, Inc. has announced the integration of Foundayo™ (orforglipron) into its weight management program, following its FDA approval on April 1, 2026. Developed by Eli Lilly and Company, Foundayo is a once-daily oral medication targeting adults with obesity or overweight conditions. This new offering allows eligible patients to access the drug through LifeMD’s partnership with LillyDirect®, facilitating direct fulfillment and shipment of prescriptions. The self-pay price starts at $149 per month, with potential reductions for patients with commercial insurance.

The significance of Foundayo’s approval lies in its classification as the second oral GLP-1 therapy approved for weight management, marking a pivotal advancement in obesity treatment options. This medication offers a practical solution for patients, enabling them to incorporate it easily into their daily routines. LifeMD’s commitment to providing comprehensive support through virtual consultations, diagnostic testing, and educational resources enhances the potential for sustained weight loss and improved metabolic health, aligning with the increasing demand for accessible, effective weight management therapies.

The introduction of Foundayo into LifeMD’s offerings underscores a notable shift in the landscape of obesity treatment, reinforcing the role of telemedicine in delivering innovative therapies. This development not only expands the therapeutic options available to patients but also signals a broader trend towards integrating digital health platforms with pharmaceutical advancements. As the field moves towards more personalized and accessible care models, the implications for drug development timelines and clinical practice are substantial, potentially accelerating the adoption of similar therapies in weight management and metabolic health.

Source: globenewswire.com